arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Evolus, Inc.

EOLS
$6.79 ▼ -0.67 (-8.91%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
41 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
60
Health
Fair
Moderately Bullish
auto_awesome

Analytical Summary

Evolus, Inc. demonstrates solid fundamentals with strength in Return on Common Equity (%). Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $447.7M
Dividend Yield —
Revenue Growth 21.2% ↗
Op. Margin -5.4% ↗
ROIC -3.5% ↗
FCF / Share $-0.06 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -5.07
info Valuation on last close. End-of-day price, Nov 5, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$84.08M
↑ +21.2% —
Net Income Profit after all expenses
$-10.67M
↑ +43.5% —
Operating Margin Operating profit as % of sales
-5.4%
↑ +42.3% 14th
FCF / Share Free cash flow per share
$-0.06
↑ +65.3% —
Long-Term Debt Long-term obligations
$156.74M
— +0.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
12
Returns
100
Financial Health ↑
71
Cash Quality ↑
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 11 years · 41 quarters